Human health and nutrition

The use of typified lactic yeast Kluyveromyces BO399 (KLUYVER B0399) is recommended in cases of abdominale aerophagy, intestinal dismicrobism, syndrome of irritable colon, dermatitis and Candida albicans.

Genome Sequence of the Probiotic Yeast Kluyveromyces marxianus fragilis B0399
Trial 214.03.04

Pubblication doi: 10.1128/genomeA.00923-16

Sara Quarella, Paola Lovrovich, Simone Scalabrin, Ilenia Campedelli, Ana Backovic, Veronica Gatto, Federica Cattonaro,c Alessandro Turello, Sandra Torriani,corresponding authora and Giovanna E. Felisa
Yogurt with Kluyveromyces B0399: Functional food
trial 186.05.02 : Survival of the functional yeast Kluyveromyces marxianus B0399 in fermented milk with added sorbic acid

pubblication:
DOI: http://dx.doi.org/10.3168/jds.2015-10084

G. Tabanelli (1), V. Verardo (1), F. Pasini (1), P. Cavina (2), R. Lanciotti (1), M.F. Caboni (1), F. Gardini (1), C. Montanari (1)
Probiotic Lactic Yeast ® Kluyveromyces B0399 : immune system stimulation, gut colonization , bifidobacteria increase and other probiotic effetcs in IBS;
Trial 143: Potential probiotic Kluyveromyces marxianus fragilis B0399 modulates the immune response in Caco-2 cells and PBMCs and impacts on the human gut microbiota in an in vitro colonic model system.

Pubblication:Appl Environ Microbiol. 2012 Feb;78(4):956-64. doi: 10.1128/AEM.06385-11. Epub 2011 Dec 9.

Simone Maccaferri(a), Annett Klinder(b), Patrizia Brigidi(a), Piero Cavina(c), Adele Costabile(a)*
Children: Stimulation of the immune system by Kluyveromyces B0399® probiotic milk yeast in the Sinerga product.
Trial 210. RETROSPECTIVE OBSERVATIONAL STUDY TO INVESTIGATE SINERGA, A MULTIFACTORIAL NUTRITIONAL PRODUCT, AND BACTERIAL EXTRACTS IN THE
PREVENTION OF RECURRENT RESPIRATORY INFECTIONS IN CHILDREN

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY Vol. 27, no. 3, 0-0 (2014)
Halitosis treatment with Kluyveromyces B0399
Trial#168: Halitosis treatment through the administration of antibiotic-resistant lactic yeast Kluyveromyces marxianus fragilis B0399 (K-B0399)
Gastric resistence and sattle in the intestine: Kluyveromyces B0399
Trial#138:Administration of a yogurt enriched with Kluyveromyces marxianus fragilis B0399 and Bifidobacterium l. BB12: a study on its impact on the intestinal microbiota of subjects with dysfunctional symptomatology

Pubblication:
Gut Microbes. 2012 Sep-Oct;3(5):406-13. Epub 2012 Jun 20.

Prof.Patrizia Brigidi*
Dr. Simone Meccaferri*
Irritable Bowel Sindrome
Trial#132 Clinical results of treatment with the lactic yeast Kluyveromyces B0399 for Irritable Bowel Sindrome. This study, based on the gathering of symtomatological data before and after the treatment, demonstrates that the prolonged use of Kluyveromyces marxianus fragilis B0399 significantly improves the clinical picture and above all improves the quality of life of these patients.

Dr. Sandro Andreoli*
Dr. Paola Lovrovich (statistical analysis)
Colonization of the gastrointestinal tract
Trial#130.1: Verification of the capacity of colonization of the gastrointestinal tract in healthy subjects, after the utililization of the lactic yeast Kluyveromyces marxianus fragilis B0399, through examination of the feces.

Giorgio Mustacchi (Oncological Centre, Local Health N1-Trieste; Trieste University) ; Antonio Miclavez ; Alessandro Turello;
Franca Bearzi;Flaviano Collavini; Paolo Valles.
Candida albicans, significant decrease.
Trial#129: Verification of the presence of Candida albicans in the gastrointestinal tract in healthy subjects, after supplementation of the lactic yeast Kluyveromyces marxianus fragilis B0399, through the examination of the feces.

Prof. Giorgio Mustacchi *1; Dr, Teresa De Monte*2; Dr. Franca Bearzi*3;Dr. Flaviano Collavini*4;Dr. Paolo Valles*5;
Dr. Paola Lovrovich*6.
Trial#125: Evaluation of the effects of a yogurt containing Kluyveromyces marxianus fragilis B0399 in patients suffering from Irritable Bowel Syndrome—a randomized clinical study controlled with placebo (abbreviate text)
This study evaluates the effects of a yogurt formulated with a new lactic yeast,
Kluyveromyces marxianus fragilis B0399, in patients suffering from IBS. A double blind, monocentric study, controlled against a yogurt containing Streptococcus t, Lactobacillus b and Bifidobacterium lactis BB1, in parallel groups, in patients affected by IBS.The subjects assigned to the treated group presented a global satisfaction significantly superior compared to the control group.

Pubblication:
Minerva Gastroenterol Dietol 2011;57(Suppl. 1 al N.2): 1-12

Principal experimenter: Prof. Enrico Roda (Bologna University – Italy)
Clinical experimenters: Prof. Gianluca Cornia, Dr. Andrea Lisotti
Statistical analysis: Eng. Antonio Maria Morselli Labate
Promoter: COOP Italia
Candida albicans: Kluyveromyces B0399 active competitor
Trial#96: In vitro test on the effect of the typified lactic yeast (Kluyveromyces marxianus B0399) on the development of Candida albicans ATCC10231.
Antibiotic resistence of the feed supplement TURVAL B0399 (probiotic with typified lactic yeast Kluyveomyces marxianus fragilisB03999).
Trial#84 The results shown in antibiogram confirm that the Kluyveromyces marxianus fragilis B0399 presents an elevated degree of resistance to the antibiotics tested.

Prof. Ann Vaughan at the University of Studies of Perugia Italy, Department of Biology and Agrodietary Biotechnologies.
Atopic Dermatitis
Trial#75:The study involved ten patients with atopic dermatitis who were administered particular strains of lactic yeasts. At the end of the study the patients treated with KLUYVER B0399 (Kluyveromyces fragilis B0399) obtained a normal range of total IgE.

Prof. A. Tulli – Director of the Clinic of Dermatology, University of Studies “G. d’Annunzio” Chieti (Italy)
Lactic yeast Kluyveromyces B0399 (Kluyver B0399) on patients suffering from irritable colon
Trial#16:The use of Saccaromyces cerevisiae and Kluyveromyces fragilis B0399 is recommended in all cases of intestinal dismicrobism induced by organic diseases and/or antibiotics, but also for putting intestinal flora back in equilibrium in the syndrome of irritable colon.

Dr. S. Andreoli – medical director of the Gastroenterologic Service of the Hospital S. Maria della Misericordia of Udine Italy;
EXPERTISE: Valutazione del lievito lattico Kluyveromyces marxianus fragilis B0399 ai sensi delle linee guida del Min. della Salute Dic 2005 All 1.(doc.depositato presso il Ministero della Salute).
Le linee guida del Ministero della Salute affermano la necessità di indicare e caratterizzare i microrganismi probiotici a livello di specie e ceppo. In questo expertise viene descritta la caratterizzazione del Kluyveromyces B0399.

Dott. Enrico Bottona [1], Dott. Giancarlo Parisi [2], Dott. Maurizio Zilli [3].
EXPERTISE: Il maiale come modello adatto alla sperimentazione applicata del sistema digerente umano.(doc.depositato presso il Ministero della Salute)
La fisiologia e la morfologia dei maiali sono molto simili a quelle umane. L’utilizzo di questa specie come modello-animale si è ormai consolidato nei più importanti campi di ricerca.

Dott.ssa Paola Lovrovich
EXPERTISE: Dosaggio giornaliero di lievito lattico Kluyveromyces BO399 nell’alimentazione umana. (doc. depositato presso il Ministero della Salute)
Dosaggio giornaliero nominale approvato dalla Commissione europea con il regolamento (CE) n. 773/2006 pubblicato sulla gazzetta ufficiale CE n.135/3 del 23.5.2006 annex 1,secondo cui la razione nominale efficace di lievito lattico Kluyveromyces BO399 in animali monogastrici è di 4,56 x 10^6 CFU al giorno.

Dr. Paolo Valles - Biologo (Trieste)
Dott.ssa Alessia Lugano - Scienze della Produzione Animale